Fountain Therapeutics

Fountain Therapeutics is a private, preclinical-stage biotech founded in 2018 and based in San Francisco. It utilizes an AI/ML-driven discovery platform to identify novel therapeutic targets for age-related conditions, with two lead programs: a topical treatment for skin atrophy and an oral therapy for muscle atrophy. The company is led by renowned aging researcher Dr. Thomas Rando and co-founder Dr. Joseph T. Rodgers, positioning it at the intersection of geroscience and computational drug discovery. Its business model is focused on developing proprietary therapeutics.

Proprietary AI/ML-driven discovery platform integrated with in vitro and in vivo screening to identify novel therapeutic targets and small molecule modulators for age-related tissue atrophy.

In aesthetics, competes with injectable fillers, neurotoxins, and topical cosmeceuticals. In muscle atrophy, faces competition from other biotechs and pharma companies developing myostatin inhibitors, SARMs, and other anabolic agents for sarcopenia. Its differentiation lies in its novel, platform-discovered targets aimed at the root causes of age-related tissue loss.